C
Christopher Metzger
Researcher at Columbia University Medical Center
Publications - 21
Citations - 1849
Christopher Metzger is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Stent & Clopidogrel. The author has an hindex of 15, co-authored 21 publications receiving 1498 citations.
Papers
More filters
Journal ArticleDOI
Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial
Gunnar Tepe,John R. Laird,Peter Schneider,Marianne Brodmann,Prakash Krishnan,Antonio Micari,Christopher Metzger,Dierk Scheinert,Thomas Zeller,David J. Cohen,David Snead,Beaux Alexander,Mario Landini,Michael R. Jaff +13 more
TL;DR: In this paper, a paclitaxel-coated balloon with percutaneous transluminant was compared with a percutaneously transluminated balloon without using a balloon.
Journal ArticleDOI
Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
John R. Laird,Peter Schneider,Gunnar Tepe,Marianne Brodmann,Thomas Zeller,Christopher Metzger,Prakash Krishnan,Dierk Scheinert,Antonio Micari,David Cohen,Hong Wang,Melissa S. Hasenbank,Michael R. Jaff,In.Pact Sfa Trial Investigators +13 more
TL;DR: The 24-month outcomes from the trial demonstrate a durable and superior treatment effect of DCB versus PTA with significantly higher primary patency, lower CD-TLR, and similar functional status improvement with fewer repeat interventions.
Journal ArticleDOI
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial
Dean J. Kereiakes,Stephen G. Ellis,Christopher Metzger,Ronald P. Caputo,David G. Rizik,Paul S. Teirstein,Marc Litt,Annapoorna Kini,Ameer Kabour,Steven O. Marx,Jeffrey J. Popma,Robert McGreevy,Zhen Zhang,Charles A. Simonton,Gregg W. Stone,Absorb Iii Investigators +15 more
TL;DR: In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis, and longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis.
Journal ArticleDOI
Stenting and angioplasty with protection in patients at high-risk for endarterectomy: SAPPHIRE Worldwide Registry first 2,001 patients
Douglas Massop,Rajesh Dave,Christopher Metzger,Williams Bachinsky,Maurice Solis,Rasesh Shah,Greg Schultz,Theodore Schreiber,Majdi Ashchi,Robbert Hibbard,Sapphire Worldwide Investigators +10 more
TL;DR: The Stenting and Angioplasty with Protection of Patients with High Risk for Endarterectomy (SAPPHIRE) randomized trial showed that carotid artery stenting (CAS) was not inferior toCarotid endartereCTomy (CEA) in the treatment of high‐surgical risk patients.
Journal ArticleDOI
Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial
Peter Schneider,John R. Laird,Gunnar Tepe,Marianne Brodmann,Thomas Zeller,Dierk Scheinert,Christopher Metzger,Antonio Micari,Ravish Sachar,Michael R. Jaff,Hong Wang,Melissa S. Hasenbank,Prakash Krishnan +12 more
TL;DR: In this article, randomized controlled trials have reported favorable 1-year outcomes with drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease when compared with stan...